Satoru Kobayashi
New York Institute of Technology, NY·Pharmacology
Doxorubicin (DOX) is a powerful cancer drug, but it can damage the heart and lead to heart failure. This is a major problem for cancer survivors.
- Fields
Pharmacology
Physiology
Medicine & Clinical Research
- Topics
doxorubicin
cardiotoxicity
cardio-oncology
- Grants
- 1 known grant, through Jun 2029
What they work on
- Measure how lysosomal membrane permeabilization (LMP) contributes to doxorubicin-induced heart injury, using an LMP reporter, the Lyso-tag lysosome isolation system and super-resolution imaging in heart cells and mice.
- Test whether protecting lysosomal membranes with imidazoline drugs, ApoM or SMURF1 reduces doxorubicin-induced LMP and cardiac damage.
- Test whether boosting cardiac cathepsin D (CTSD), a lysosomal enzyme that activates other enzymes, rescues heart function after doxorubicin, using transgenic mice, CTSD knockout mice and a CTSD inhibitor.
- Determine whether restoring CTSD maturation with imidazoline agonists or prosaposin (PSAP) overexpression restores lysosomal function and protects against doxorubicin cardiotoxicity.
More about the research
One emerging explanation centers on lysosomes, the cell's acidic recycling compartments. In lysosomal membrane permeabilization (LMP), the lysosome's membrane becomes leaky. Earlier studies focused on digestive enzymes escaping into the cell and triggering cell death. This project instead asks whether the real harm comes from the lysosome losing its acidity and its ability to digest material inside heart muscle cells (cardiomyocytes).
Why it matters
Cancer survivors treated with doxorubicin risk heart damage and heart failure. Showing that leaky lysosomes and too little cathepsin D activity drive this damage could point to new ways to protect the heart during chemotherapy. Options suggested by the grant include stabilizing lysosome membranes or restoring cathepsin D function. Such strategies could improve quality of life for people treated with this drug.
Known grants
From NIH and NSF research grants. Labs often have other funding we can't see.
Closest labs
Keykavous Parang
Chapman University, CA·Pharmacology
Compare how five peptide-doxorubicin conjugates (PDCs) differ in killing cancer cells versus heart muscle cells, measuring reactive oxygen species, cell death (apoptosis) and calcium release.
Lindsay Edwards
Duke University, NC·Medicine & Clinical Research·Early-career
Optimize a machine learning pipeline that predicts cardiomyopathy in pediatric cancer survivors from routinely collected echocardiographic and clinical data.
Jidong Fu
Ohio State University, OH·Medicine & Clinical Research
Characterize how Masir, a membrane-associated long noncoding RNA, protects heart muscle cells from ischemic injury by enhancing membrane repair, and assess its safety in mouse models.
The school
New York Institute of Technology: 4 labs on PI Pages, $7M a year on research, 34 research doctorates a year.
Reach out
A start for your email. Fill in the brackets.